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InTrOduCTIOn
The management of multiple sclerosis (MS) has 
been a neurology success story for the past 25 years. 
Advances in understanding of the disease mecha-
nisms and the dynamic nature of the disease have 
brought around 12 disease-modifying therapies 
(DMTs) to market in many countries.
However, treatment is hampered by adverse 
effects and by limited evidence of efficacy in more 
advanced ‘progressive’ MS. Some patients do not 
receive DMTs for years after diagnosis, or are told 
medication can no longer help as their disability is 
worsening. The cost of DMTs is also a significant 
issue, especially in low-income and middle-income 
countries.
MS affects an estimated 2.5 million people world-
wide, with a higher prevalence and incidence in the 
northern hemisphere.1 Patients with MS now have 
a longer life expectancy,2 3 in part because of earlier 
treatment. Accounting for comorbidities such as 
age-related vascular disease will become increas-
ingly important in patient management.4
The Journal of Neurology, Neurosur-
gery &  Psychiatry brought together a panel of 
experts on World MS Day 2017 to discuss the 
importance of time in MS—timing of initiation and 
withdrawal of disease-modifying treatment, time 
to consider contributory factors such as vascular 
disease, and the time and cost burden of MS. This 
paper, which originated in the round table discus-
sion, reviews the following:
 ► latest thinking in timing of disease management
 ► how treatment and prevention of vascular 
injury may buy additional time for people with 
MS
 ► new data about the true economic and social 
burden of the disease for people with MS and 
their carers.
TImIng Of dIsease managemenT: The 
Case fOr sTarTIng dIsease mOdIfICaTIOn 
TreaTmenT early
MS damages the whole brain, and damage begins 
from the start of the disease. Every system in the 
brain—myelin, white matter, neurones, axons and 
blood vessels—is damaged by MS.5–7 Brain atrophy, 
both in the cortex and the white matter, is progres-
sive and accelerates over time.8 Evidence from MRI 
scans shows that even at the earliest stages of MS, 
people lose brain volume, and that it is lost at the 
same rate as someone with later stage disease.9
Recent painstaking research using donated brain 
tissue found that people who die with MS have 
a neuron count 39% lower than people without 
MS,10 due at least in part to damage to fibre tracts 
and subsequent retrograde/anterograde neuronal 
degeneration.11 This loss is strongly associated 
with the thickness of the cortical and deep grey 
matter,12 13 which suggests cortical volume measures 
using MRI that are predictive of clinical outcome 
indeed reflect neuronal loss.14
While repair of brain plaques can be detected in 
the early stages of MS, the regenerative potential 
of the brain is limited and becomes less effective 
with age.15–17 Results of trials attempting to induce 
regeneration have so far not been very promising.18
All these suggest that swift action to prevent or 
slow damage to the brain is crucial. Clinicians must 
act before the disease causes irreparable damage 
to the brain, and before the brain’s limited mech-
anisms for repair are damaged. There is increasing 
consensus about the importance of early interven-
tion to maximise lifelong brain health.19
So when should treatment start and what criteria 
should guide a clinician’s decision as to when to 
offer disease-modifying treatment? Clinicians often 
think of MS progression in terms of walking ability 
and judge the progress of MS by performance on 
tests such as the timed 25-foot walk. However, for 
people with MS, cognitive health is of major impor-
tance and is impaired before walking ability. Cogni-
tive deficit, not walking ability, has the biggest 
impact on the employment status of people with 
MS.20
Cognition decreases over time with MS, right 
from the outset.21 Even people with radiographi-
cally isolated syndrome suggestive of MS may have 
hidden cognitive deficits.22 On the other hand, 
people with MS and normal cognitive function 
may also have compromised brain functioning,23 
putting them at impending risk of collapse. While 
early structural damage might in many patients 
preserve overall network efficiency, its continuous 
accumulation during the course of disease leads to 
an inevitable decrease in such efficiency (increased 
or additional recruitment of brain areas and/or 
altered connectivity between regions).24 Impor-
tantly, cognitive impairment might not be apparent 
until brain network efficiency reaches a certain 
threshold, which seems to be different from indi-
vidual to individual according to, among other 
factors, premorbid cognitive reserve.25
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Indeed, evidence shows that children who go on to develop 
MS in adulthood show evidence of poorer school performance, 
suggesting that the disease could be affecting cognition 5–10 
years before any clinical manifestation can be seen.26
If cognitive decline starts so early, we need to begin treating 
MS with disease-modifying drugs as soon as we are aware of it.
The best long-term evidence that we have, from follow-up 
studies on participants in early trials of interferon beta, showed a 
clear improvement in mortality for patients who started the drug 
1 or 2 years earlier.27 We can also see an impact on disability. 
Long-term follow-up of early trials of natalizumab showed that, 
even after 5 years, patients who were in the initial treatment 
group had a lower Expanded Disability Status Scale (EDSS) score 
than those who were initially treated with placebo and started 
active treatment 2 years later.28
The impact of treatment may decrease as the disease unfolds 
in line with the natural history of MS, where we can see that 
the impact of relapses on disability progression is higher in the 
earlier stages of the disease.29
A recent positive trial of siponimod in secondary progressive 
MS further suggested that, even in the latter phases, disease 
duration is a key factor in determining the impact that drugs 
can make. The study found the effect of siponimod in delaying 
confirmed disability progression decreased as disease duration 
increased, such that the only patient group with significant 
decrease in confirmed disability progression on drug treatment 
were those diagnosed within 10 years.30
TImIng Of dIsease managemenT: The Case fOr 
COnTInued TreaTmenT Of prOgressIve dIsease
One inference of the ‘treat early’ concept is that, beyond a certain 
point of disability, usually expressed as around stage 3 or 4 on 
the EDSS, the disease can no longer be modified31 and DMT is 
therefore without merit.32 That inference has more recently been 
challenged following review of past trial evidence33 34 and new 
data,35 36 indicating that even people at a more advanced stage of 
MS may benefit from DMT.
The difference in responsiveness to DMT between upper limb 
(and cognitive problems) and lower limb (and, for example, 
bladder) dysfunction suggests a degree of length dependency of 
nerve damage.33 37 38 Evidence suggests nerve fibre tracts to the 
lower spine are more likely to be damaged in more places than 
shorter nerve fibre tracts.37 39 Moreover, more than 50% of corti-
cospinal tract fibres have already terminated once they approach 
the neck portion of the spinal cord, providing a naturally higher 
redundancy of tracts supplying the arms and hands, and other 
important for functions such as swallowing and speech.38 40 41
We are now seeing increasing evidence that disease modifica-
tion is possible at later stages of disease, even after walking func-
tion has been lost.33 34 42 43 Patients value upper limb function 
and are keen to be included in studies after the loss of walking 
ability—a recent survey showed 95% of patients disagree with 
the idea that wheelchair users should be excluded from MS 
studies.44
A study published last year showed that the anti-CD20 
monoclonal antibody ocrelizumab can slow deterioration in 
people with primary progressive MS, with a 25% reduction in 
EDSS-measured disability progression at 12 and 24 weeks.45 
Looking at upper limb function, the study reported a 44% differ-
ence in upper limb function between treated and non-treated 
patients, in line with the length dependency hypothesis.46
Ocrelizumab is the first drug to have been licensed for primary 
progressive MS. A phase III trial of fingolimod (INFORMS) 
failed to show an overall impact of the drug on disability in 
progressive MS.47 However, case studies from the trial suggest 
that some patients do indeed benefit from the treatment. One 
patient enrolled in the INFORMS trial had a catastrophic dete-
rioration 4 months after discontinuing fingolimod as a result of 
the trial termination, which was due to the negative outcome of 
the cohort on the primary endpoint (EDSS). She experienced a 
step change in disability level from EDSS 6.5 to 8 and hand func-
tion in particular. Subsequent treatment with off-label cladribine 
helped her regain some of the lost function.48
Evidence from MRI and other studies clearly shows that the 
concept of progressive MS49 as a ‘non-inflammatory stage’ of 
MS is wrong.50 Earlier pathology studies demonstrated signif-
icant association between inflammation and axonal damage, 
regardless of whether the patient had progressive or relapsing 
MS.51–53
While anti-inflammatory disease-modifying treatment should 
be started as early as possible, it should not necessarily be given 
up when patients develop progressive MS. To demonstrate 
benefit, trials will need to include outcomes that are sensitive 
to functions that can be protected or recovered at an advanced 
stage of the disease, including upper limb function, dexterity, 
swallowing and speech.54 High-quality surrogate indices, such 
as the impact of new compounds on MRI indices of brain or 
spinal cord volume, are useful in phase II trials to estimate likely 
clinical benefit.55–57
It is important to bear in mind that clinical and surrogate 
indices should reflect changes that are meaningful for people 
with MS. The concept of ‘treat early and never stop’ should be 
mindful of the adverse effects associated with DMTs—predomi-
nantly lowered immune function and increased susceptibility to 
infection and neoplasms.1
For a fully informed treatment choice, people with MS need 
time for comprehensive education about all aspects of their 
DMT management. Early treatment with a highly effective DMT 
may be beneficial in terms of disease control but at the trade-off 
of increased risk of adverse effects. For example, alemtuzumab 
leads to no evidence of disease activity over years in more than 
60% of patients and a nearly normalised brain atrophy rate in 
many,58 but the risk of secondary autoimmunity can reach nearly 
50%.59
The long-term value of such an intervention, compared with 
an escalation strategy, remains to be confirmed. The number 
of effective compounds has increased significantly over recent 
years, and high efficacy is not now always synonymous with high 
risk.60–62 Patients and physicians should keep an open mind, be 
prepared to monitor efficacy and adverse effects, and switch 
DMT as required.
Early detection and diagnosis may allow for suppression of 
inflammation to a degree that could prevent or stop the devel-
opment of neurodegeneration. For example, data from the 
alemtuzumab programme indicate that such high efficacy with 
long-term remission can be achieved in some patients.59 63
ageIng wITh ms: TIme TO InTervene In vasCular 
dIsease prevenTIOn
MS is a chronic disease, in the majority of cases, initially charac-
terised by acute bouts of inflammation that translate into tran-
sient neurological dysfunction. At some point—often around age 
40–50—the clinical phenotype may transition to a progressive 
phase,64–67 during which further mechanisms, over and above 
focal inflammatory demyelination, contribute to disease evolu-
tion.68 69 These include mitochondrial dysfunction,68 hypoxia,70 
3Cerqueira JJ, et al. J Neurol Neurosurg Psychiatry 2018;0:1–7. doi:10.1136/jnnp-2017-317509
Occasional essay
iron accumulation68 and fibrogen deposition,71 and contribute 
to amplify neurodegeneration,68 72 particularly in late-stage 
disease or older patients, where inflammation is less promi-
nent53 73 and neuronal loss seems to be relatively independent 
from demyelination.10
Older age seems to influence the clinical phenotype, patients 
with progression from disease onset being typically older than 
those with a relapsing remitting onset. Age influences the onset 
and transition into clinical progressive MS and the pathological 
hallmarks and mechanisms which feature progressive disease, 
despite the initial clinical phenotype.74
Vascular disease is also an age-related phenomenon, with an 
accumulation of atheroma in blood vessels from an early age, 
which can lead later in life to heart disease (around the age of 50s 
and 60s) and brain damage (after the age of 60).75 Vascular risk 
factors such as hypertension, diabetes and dyslipidaemia also 
contribute to the accumulation of vessel atheroma and have 
been linked to changes in the brain, including brain volume loss, 
white matter lesions and small haemorrhages visible on  the MRI 
scans of people with vascular risk factors but no MS. In turn, 
these changes correlate with cognitive dysfunction and walking 
impairment.76 77
A key and unresolved question is whether people with MS have 
an increased risk of vascular disease such as stroke, compared 
with people without MS.78–81 Epidemiological data suggest that 
cardiovascular disease is an important cause of death in MS,82 
and that people with MS have a small increase in risk of stroke.80 
However, this finding should be treated with caution, as it could 
be due to surveillance bias or the impact of immobilisation that 
features in late-stage MS.78 Morphological changes in brain 
blood vessels, such as vessel wall thickening, have been described 
in people with MS.83 84 As in other inflammatory disorders such 
as rheumatic diseases,85 cerebral vessels exposed to MS chronic 
inflammation could be prone to atheroma and atherosclerosis. 
This hypothesis is to be investigated.
Even if patients with MS do not have a greater risk of vascular 
disease than the general population, 17% of all patients with MS 
have hypertension and 8% have hyperlipidaemia at the time of 
diagnosis,86 with older patients with MS having a higher preva-
lence of these vascular risk factors.4
Vascular risk factors and disease are associated with worse 
outcomes in people with MS. It is well known that smoking 
reduces time to secondary progression, but perhaps less well 
known that the presence of any vascular risk factor is linked to 
reduced time to walking disability.87 88 The exact mechanisms 
underlying the effect of vascular risk factors in disability are 
unclear, but it is possible that blood vessels already exposed to 
chronic inflammation are put under additional pressure through 
vascular risk factors.89
It is not difficult to see why this might be. Cerebral blood 
vessels provide oxygen and nutrients to nerve cells, and are key 
intermediaries between nerve cells and the immune system. 
Damaged blood vessels contribute to nerve hypoperfusion and 
hypoxia, and there is evidence of brain hypoperfusion in MS. 
Maps of cerebral blood flow show that areas of low blood 
perfusion colocalise with both T1 and T2 MS lesions,90 and MS 
lesions tend to accumulate in ‘watershed’ areas (areas between 
two vascular territories, where there is hypoperfusion).91
MS and small vessel cerebrovascular disease may be difficult 
to distinguish.92 93 More specific markers are required to enable 
clinicians to distinguish between MS progression that might be 
treated by DMTs and cerebral damage that is a result of cerebro-
vascular disease. While clinical studies of vascular risk factors 
in MS are hard to envisage, large-scale epidemiological studies, 
drawing on big data from patient databases, may provide some 
answers. This might help to untangle the ways in which each 
vascular risk factor has an impact on the progression of MS.
Although the association between vascular disease and 
MS is not fully understood, it is possible that vascular risk 
factors94 95 or vascular pathology can cause additional damage 
to the brains of people with MS, over and above that caused 
by MS alone.70 96 97 Although this needs further confirmation, 
information about patients’ vascular status should be incorpo-
rated into clinical trials. MS is a heterogeneous disease, and at 
the individual level the time to reach the secondary progres-
sive phase is variable. The role of age-related vascular disease 
on MS progression onset and phenotypic presentation has still 
to be investigated. If time matters in protecting the brain from 
inflammation-related damage in relapsing remitting MS, it also 
matters in protecting the brain from additional damage from 
vascular disease.
We know that patients who stop smoking sooner have better 
outcomes.98 It is time to take other vascular risk factors seri-
ously. Clinicians should talk to patients about vascular risk and 
encourage them to take preventive action in the form of smoking 
cessation, diet and exercise. Vascular risk factors or morbidities 
such as hypertension should be assessed and treated, before 
they begin to add to the burden of brain damage. Proper, timely 
interventions in patients’ vascular health may help buy addi-
tional time to treat MS. Integrated care requires consideration 
of the body outside of the nervous system, as well as the nervous 
system and brain.
COsTs and burdens Of ms
Part of the struggle to ensure everyone who needs appropriate 
treatment for MS can access it stems from concerns around 
costs. Uncovering the true benefits of MS treatment could help 
the MS community to make the case for funding of treatment.
Because MS is a disease in which disability accrues slowly, yet 
studies of treatment are often of only 2–3 years’ duration, it can 
be challenging to show the full extent of the benefits. Health 
economists look for data that demonstrate quality of life gains 
for the individual affected, yet this may not capture the full 
extent of the economic benefits of treatment—not only for the 
health service and the person being treated, but for their carers 
as well.
MS is an expensive disease, and the costs rise sharply in line 
with increased disability and plummeting quality of life. Two 
new studies have gathered more data about the burdens and 
costs of MS in Europe. The aim is to demonstrate evidence of 
the impact of an effect of treatment on disease progression that 
will prevent or delay patients reaching a disease state with higher 
costs and lower quality of life.
The first of these studies is the largest study ever performed 
of MS disease burden and treatment.99 The observational, 
cross-sectional study included data from 16 808 patients from 16 
countries across Europe. Patients were contacted by national MS 
societies and provided data collected by questionnaires, either 
online or in printed form. The study collected information on 
patient characteristics, disease type, use of resources and loss of 
resource (including work capacity) over the previous 3 months’ 
period. The EDSS was used to stratify patients by disease level.
Results were highly heterogeneous between countries, 
including sample size, average age and disability level. The 
results also reflected differences in healthcare systems and 
informal care traditions in different countries. However, the 
findings confirmed the relationship between costs and disability, 
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a finding that costs increase on average fivefold between mild 
and severe MS.
One clear difference was in the proportion of patients using 
DMTs. Spain, France and Portugal had the highest proportion 
of patients taking these medications. These results may have 
reflected the average level of disability and disease type in the 
cohort of each country. The UK cohort, for example, had a 
higher proportion of patients with progressive disease, which 
may explain the relatively low proportion using DMTs. Overall, 
the study found, as might be expected, that DMTs are more 
frequently used at lower EDSS scores, and very little used in 
people with higher EDSS scores. Fatigue and cognitive diffi-
culties have a major effect on patients’ productivity. The study 
results suggest that renewed focus on fatigue and cognitive func-
tion is critical. They are not incidental symptoms, but a funda-
mental manifestation of MS which should be actively managed.
The study found that many patients of working age were 
not working, and that this reached 50% of the cohort at EDSS 
score of 3.5. The implication is that MS affects employment 
status before physical disability sets in. Some 95% of patients 
complained of fatigue and cognitive difficulties. Given the diffi-
culty of objectively assessing one’s own cognitive function, this 
may be an underestimate.
The study findings on healthcare resource use provide an 
insight into different healthcare models. The proportion of 
patients who reported having seen a neurologist in the past 
3 months varied considerably, from 81% in Germany to 25% in 
the UK. This correlated inversely with use of specialist nurses—
where patients frequently saw neurologists, they were less likely 
to have seen an MS nurse or a physiotherapist.
The study showed wide variation in the models of care. While 
data from a ‘snapshot’ cross-sectional study are difficult to eval-
uate, some countries have done work to evaluate the cost-effec-
tiveness of different models of care. The results may help the MS 
community to develop an optimum model of care, which might 
cover access to DMTs, early treatment, high-quality services and 
the optimal balance between different healthcare professionals. 
The heterogeneity of findings suggests that healthcare consump-
tion is currently more influenced by systems and tradition than 
by the disease itself.
Some countries had a very high percentage of informal care, 
possibly relating to the traditional care models in that country. 
Others had less use of informal care, which might relate to more 
developed formal care services or more access to formal care 
services. For most countries, use of informal care increased with 
increasing disability scores. In some countries, informal carers 
were providing 150 hours a month of care to patients—the 
equivalent of full-time employment.99
Further insight into the experience of patients and carers 
came from the International Multiple Sclerosis Study (IMPrESS) 
, which included an online survey of 1152 people with MS and 
265 carers from 19 countries.100
Most patients had relapsing MS, although some were unsure, 
reflecting the confusion around classification of MS. Most 
patients were treated with DMTs (around 80% of those with 
relapsing MS and, surprisingly, almost all those with primary 
progressive MS). However, only a fraction of these people were 
taking oral DMTs. Patients who had received prompt treat-
ment—within 12 months of first symptoms plus confirmatory 
MRI evidence—were more likely to be taking oral DMTs and 
reported fewer hospital admissions, compared with those whose 
treatment was delayed beyond 12 months.
The study revealed a ‘care gap’ between the amount of care 
people received and the amount they believed they needed. 
Questions about quality of life and disability score showed that 
the EuroQol Five Dimensions questionnaire may not neces-
sarily capture what matters most to patients—notably fatigue, 
weakness, balance and dizziness. Patients say these things are 
important to them, yet they are not captured by generalised 
quality of life questions. Patients tend to rate themselves rela-
tively highly on quality of life, even when their disability score 
suggests they are not doing so well.
The study found that patients rate access to information 
very highly and tend to look online for information, primarily 
from MS-specific organisations or charities. Patients felt they 
needed good-quality information to participate in shared deci-
sion-making. While they valued the opinion of the clinician, 
they also wanted the opportunity to discuss options with them, 
and 67% said they wanted to be active in the decision-making 
process and management of their care.
The figures about informal care backed up the findings of the 
bigger study, showing a huge impact on carers’ economic activity, 
with an annual figure of €31 653 loss of productivity. Despite 
this, carers tended not to rate their caring duties as burdensome.
Taken together, these studies demonstrate that the greatest 
costs of MS are not the drugs to treat the disease, but the cost of 
informal care and loss of productivity, both of patients and their 
informal carers. Bringing new evidence about these costs into 
health technology assessments would be a step forward in recog-
nising the contributions of informal care and the costs incurred.
early evIdenCe fOr eCOnOmIC analysIs
Despite the advances made in DMT for patients with relapsing 
MS over the past 25 years, patients who develop secondary 
progressive MS which make up to more than half of the MS 
population do not currently have access to a therapy licensed 
for their treatment. This would target progressive MS besides 
Primary MS..101
This is in part a reflection of our limited understanding of 
the mechanisms underpinning progression, in addition to the 
complex hurdles that therapies must overcome to gain a licence 
for an indication and to be judged both cost-effective and afford-
able by those meeting the costs of therapy.
Based on the indication for which the licence is granted—
which with MS is often restricted by disease severity or stage—
individual countries will determine whether to reimburse the 
drug through their healthcare system, using health technology 
assessment. This process, which usually takes at least 12 months, 
will consider cost-effectiveness and value for money and will 
look for added therapeutic value.
The two further decision-makers, after the regulatory author-
ities and the payment authorities have had their say, are the 
prescribers—who consider the likely performance of the drug 
compared with other therapies for the individual patient—and 
potentially the patient, who may have to decide whether he or 
she is willing or able to pay for the treatment (if they pay directly 
for medical care) and whether to adhere to treatment.102
How can this process be speeded up so that effective therapies 
can get to the patients who benefit from them more quickly?
Phase II trials can be extended to look at disability endpoints 
and provide longer term data, which may be helpful for health 
technology assessment. Phase III trials tend to include disability 
endpoints and the sustained effect of therapies on disability. 
However, while these trials can look at impairments—what 
level of disability scores people have and how these change over 
time—they are less good at considering how impairments affect 
the patient’s activities and role in society. This is complicated, 
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because two patients with similar impairments may feel they 
have different levels of disability, perhaps based on external 
factors such as their social support and expectations. This makes 
it very difficult to truly measure the impact of disability.103
Tools that assess the effects of limitations on activities and 
participation in society do exist, but are not specific enough to 
be sure that the limitation is caused by MS. A combination of 
MS-specific disability measures and these wider tools might give 
us a better picture, but this would be excessively cumbersome for 
use in routine assessments. Most endpoints currently measured 
look at clinical signs, not functioning. Global functional tools 
are variable and have a bias towards diagnosis of depression. 
There is a need to develop better tools to measure disability and 
its effect on patients’ functioning and societal role, if we are to 
provide good evidence of the true burden of MS on society, and 
the related cost–benefit of therapies.
Meantime, we need to find a way to get therapies that are 
licensed for one indication and now off-patent (such as statins) 
but may have useful activity for MS, into the health technology 
appraisal system. At present, there is no incentive for a manufac-
turer to fund an expensive clinical trial of statins for treatment 
of MS, and most health technology assessment systems will only 
assess therapies licensed for the indication being proposed.104
COnClusIOn
New insights about the timing and duration of MS therapies, 
and about the importance of comorbidities, present us with great 
opportunities to make significant improvements to the lives of 
people with MS.
While the research we outline highlights a significant level 
of unmet need in a relatively young and economically active 
population, this information can be used to press for more wide-
spread adoption of the principles of early effective treatment and 
long-term follow-up to keep disease activity in check. This adop-
tion must come now not just from clinicians and patients, but 
also from drug regulators and payers (insurers and tax-funded 
healthcare).
More widespread adoption of these principles could help us to 
build on the successes of the therapeutic advances we have seen 
over the past 25 years, ensuring that everyone who can benefit 
from treatment does so and that no patients are left behind. We 
already know that ‘time matters’ when treating MS. Now it is 
time to take that message to those planning services, regulating 
healthcare technologies and setting the healthcare agenda.
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